Human retinal pigment epithelial cell therapy - Stemedica Cell Technologies

Drug Profile

Human retinal pigment epithelial cell therapy - Stemedica Cell Technologies

Alternative Names: Stemedyne™ RPE

Latest Information Update: 14 Apr 2015

Price : $50

At a glance

  • Originator Stemedica Cell Technologies
  • Class Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Glaucoma; Macular degeneration; Retinitis pigmentosa

Most Recent Events

  • 24 Mar 2015 Stemedica Cell Technologies in-licenses Preservation by Vaporization (PBV) technology from Universal Stabilization Technologies
  • 10 Sep 2009 Clinical trials in Retinitis-pigmentosa in Russia (Intraocular)
  • 10 Sep 2009 Clinical trials in Macular degeneration in Russia (Intraocular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top